Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
U.S. Sen. Robert Menendez first ran for the U.S. House in 1992 and has been raising money for his campaigns ever since. He has brought in more than $50 million during that time, according to the Center for Responsive Politics , a Washington research group.
Democratic control of U.S. Sen. Bob Menendez's Senate seat in Democrat-leaning New Jersey could hinge on how well he can convince voters they need him to stand up to President Donald Trump, and on whether Republican challenger Bob Hugin can make a case the electorate should dump the incumbent over tossed-out corruption charges. Victories on Tuesday by Menendez and former Celgene Corp. chief executive Bob Hugin set the stage for New Jersey's only statewide race in November as Trump and national Republicans defend a narrowly divided Senate.
Democratic control of U.S. Sen. Bob Menendez's Senate seat in Democrat-leaning New Jersey could hinge on how well he can convince voters they need him to stand up to President Donald Trump, and on whether Republican challenger Bob Hugin can make a case the electorate should dump the incumbent over tossed-out corruption charges. Victories on Tuesday by Menendez and former Celgene Corp. chief executive Bob Hugin set the stage for New Jersey's only statewide race in November as Trump and national Republicans defend a narrowly divided Senate.
WASHINGTON -- U.S. Sen. Robert Menendez is "leading a lavish lifestyle courtesy of corruption." Former Celgene Corp. executive Bob Hugin is a "greedy drug company CEO."
These bearish sentiments first started with Valeant Pharmaceuticals, then Gilead and Turing Pharmaceuticals, and are now adversely affecting ETFs that hold any of these or their peers/competitors. It is my contention that the market is accustomed to common arbitrage opportunities, and when an even-driven opportunity emerges masking itself as a headwind, investors flee.